Study wrapper · #178
Temporal Trends and Clinical Characteristics of Incretin-Based Therapy Use in Women With Polycystic Ovary Syndrome: A Real-World Cohort Study From a Polish Private Healthcare Network.
Editor's note
A large real-world cohort (38,263 women with coded PCOS in a Polish private network) describing how fast GLP-1 and GIP/GLP-1 receptor-agonist prescribing has grown in this population. This is a descriptive electronic-health-record study of prescribing patterns, not an efficacy or outcomes trial: it tells us who is being prescribed these drugs and how the trend is moving, not whether they help PCOS-specific endpoints. Researchers reported that recorded initiation within a year of PCOS diagnosis rose from 0.14% in 2018 to 5.97% in 2024, that users had higher BMI and greater comorbidity burden than metformin-only or untreated women, and that only 11.5% carried a type 2 diabetes code, suggesting weight- and cardiometabolic-driven use rather than glycaemic indication. The value here is a market and practice signal. Its limits are real: EHR prescribing records do not confirm dispensing, adherence, or clinical response, and a single private network in one country may not generalise. The authors themselves call for dispensing, persistence, safety and outcome studies.
Plain-language abstract
GLP-1 medicines (and the dual GIP/GLP-1 drug tirzepatide) are increasingly used for weight and metabolic problems, but how often they are prescribed to women with polycystic ovary syndrome (PCOS) has been unclear. Researchers reviewed electronic health records from a large Polish private healthcare network, covering 38,263 adult women with a PCOS diagnosis code, and focused on those diagnosed in 2018-2024 to see who started these drugs within a year. This kind of study describes prescribing patterns; it does not test whether the drugs improve PCOS symptoms. Overall, 11.9% had a record of one of these prescriptions and 42.8% received metformin. Among the newer-drug users, three-quarters also took metformin, but only 11.5% had a diabetes diagnosis, suggesting the drugs were mostly used for weight and metabolic reasons. Users tended to weigh more (median BMI 31.2 versus 26.3 and 22.1) and had more other health conditions. Prescribing within a year of diagnosis rose sharply, from 0.14% in 2018 to 5.97% in 2024. The authors say further studies on actual dispensing, how long people stay on treatment, safety and outcomes are needed.